-
-
-
-
-
-
-
BiondVax Pharma (BVXV) Rebrands as Scinai Immunotherapeutics; Focuses on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
-
-
-
-
-
-
-
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
-
-
-
-
-
-
-
BiondVax to Present at BIO-Europe Spring
-
-
-
-
-
-
-
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
-
-
-
-
-
-
-
BiondVax Announces Closing of $8 Million Underwritten Public Offering
-
-
-
-
-
-
-
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
-
-
-
-
-
-
-
BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco
-
1,167,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

